Norris Medicines Ltd Financials
Company Logo

Norris Medicines Ltd Financial Statement

Norris Medicines Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue1.27
Operating Expense1.41
Net Profit-0.36
Net Profit Margin-28.35
Earning Per Share-0.36
EBIDTA-0.15
Effective Tax RateTBA

Norris Medicines Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual5.64
Operating Expenses Annual5.82
Operating Profit Annual-0.16
Interest Annual0.37
Depreciation0.57
Net Profit Annual-1.19
Tax Annual0.09

Norris Medicines Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.02
Cash Flow from Operations0.17
Cash Flow from Investing0.05
Cash Flow from Financing-0.20
Cash Flow at the End0.04

Norris Medicines Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)-2.84
PBIT Margin (%)-12.94
PBT Margin (%)21.99
Net PROFIT Margin (%)-21.10
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-14.14
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)0.67

Norris Medicines Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual5.79
Total Current Assets Annual6.14
Non Current Assets Annual8.04
Total Shareholders Funds Annual-13.63
Total Assets Annual14.19

Norris Medicines Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Dec 8, 2024, Norris Medicines Ltd has a market capitalization of 13.60 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Norris Medicines Ltd is debt-free with a debt-to-equity ratio of -1.58.
In FY 2023 , Norris Medicines Ltd recorded a total revenue of approximately 5.64 Cr marking a significant milestone in the company's financial performance.
Norris Medicines Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and -0.3% annually, respectively..
Norris Medicines Ltd's current PE ratio is -11.43.
Norris Medicines Ltd's ROCE averaged -4.2% from the FY ending March 2022 to 2024, with a median of -6.8%. It peaked at 3.4% in March 2023, reflecting strong capital efficiency over the period..
Norris Medicines Ltd's latest EBIT is Rs. -0.73 Cr, surpassing the average EBIT of Rs. -0.37 Cr over the 5 years..
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions